Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07043803
NA

Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

Sponsor: University of Pittsburgh

View on ClinicalTrials.gov

Summary

The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.

Official title: Reduction of Anticholinergic Medications Project (RAMP) Among Persons With Schizophrenia or Other Psychiatric Disorders Across UPMC Behavioral Healthcare Partner Organizations Using a Stepped-wedge, Randomized Trial Study Design.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

111

Start Date

2025-07-16

Completion Date

2026-05

Last Updated

2025-08-06

Healthy Volunteers

No

Interventions

OTHER

Reduction of anticholinergic medication

Shared decision making between the patient and prescriber will determine the timing and speed of reduction over a period of 12 to 16 weeks. Some patients will be discontinued from these anticholinergic medications (benztropine/trihexyphenidyl), others will be tapered from their original dosage but not completely discontinued, and some patients may not be able to taper the anticholinergic medications at all.

Locations (4)

Western Behavioral Health of the Alleghenies

Altoona, Pennsylvania, United States

UPMC Western Behavioral Health at Safe Harbor

Erie, Pennsylvania, United States

Western Behavioral Health Mon Yough

McKeesport, Pennsylvania, United States

Comprehensive Recovery Services (Pittsburgh) of Western Psychiatric Hospital, Ambulatory Clinics and Residential Programs - UPMC, Pittsburgh, PA

Pittsburgh, Pennsylvania, United States